TABLE 2.
Summary of UL89 mutations selected in vitro
| Amino acid substitutiona | GW275175X (nb = 6) |
Tomeglovir (n = 8) |
Letermovir (n = 2) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of exptsc | Passage no.d | Lowest concn (μM)e | No. of expts | Passage no. | Lowest concn (μM) | No. of expts | Passage no. | Lowest concn (μM) | |
| N320H | 1 | 19 | 8 | ||||||
| N329S | 1 | 10 | 4 | ||||||
| I334V | 1 | 5 | 6 | ||||||
| D344E | 6 | 7 | 4 | 1 | 24 | 30 | |||
| C347S | 4 | 15 | 30 | ||||||
| T350M | 1 | 17 | 30 | ||||||
| R351H | 1 | 18 | 30 | ||||||
| M359I | 1 | 13 | 0.8 | ||||||
| V362M | 8 | 12 | 8 | ||||||
| H389N | 1 | 8 | 8 | ||||||
| N405D | 3 | 5 | 4 | ||||||
a
Excludes Q11H, which was coselected with V362M in experiment M200 (Fig. 1).
b
n, total number of experiments performed.
c
Number of experiments in which the mutation was detected.
d
Median passage number at which the mutation was first detected.
e
Lowest drug concentration at which the mutation was first detected.